Navigation Links
Sinovac to Host Conference Call to Report Third Quarter 2011 Unaudited Financial Results
Date:11/7/2011

BEIJING, Nov. 7, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2011 before market open on Monday, November 14, 2011. The Company will host a conference call on Monday, November 14, 2011 at 8:00 a.m. EST (November 14, 2011 at 9:00 pm China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11 a.m. EST on November 14, 2011 to November 28, 2011 at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (international) and reference the replay pin number 382617.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at www.sinovac.com. A webcast replay can be accessed on the corporate website beginning November 14, 2011 and the replay will remain available for 30 days.

About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), pneumococcal polysacchari
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sinovac Reports Unaudited Second Quarter 2011 Financial Results
2. Sinovac Announces Management Changes
3. Sinovac Holds 2011 Annual Shareholders Meeting
4. Sinovac Appoints Kenneth Lee to Board of Directors
5. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
6. Sinovac Reports Unaudited First Quarter 2011 Financial Results
7. Sinovac Presents at Two Investor Conferences in May 2011
8. Sinovac Files Annual Report on Form 20-F
9. Sinovac Participates in UBS Greater China Healthcare Corporate Day
10. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
11. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... DIEGO , July 30, 2014  Eisai Inc. and ... that an article based on post-hoc analyses from the three ... While on Lorcaserin, Diet, and Exercise as a Predictor of ... issue of Obesity , the official peer reviewed journal ... to identify whether there is an early treatment milestone that ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... funding commitment from a prominent international research and ... focus on promoting innovative research-based initiatives, including those ... nasal spray for the delivery of naloxone that ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... announced today that the Company,s Chairman and CEO Byron ... taking place September 7-9.  BioBDx manufactures and markets the ... related to deficits in response inhibition. The ... measurement of hyperactivity, impulsivity and inattention as an aid ...
... NEW YORK, Aug. 31, 2011 The Prix Galien ... in biopharmaceutical research and development, announced today that Dr. ... Humanum Award during the 5th Annual Prix Galien USA ... of other awards honoring companies who have made innovative ...
Cached Medicine Technology:BioBDx to Present at the 2011 BioPharm America Conference 2Dr. Paul Farmer Selected as 2011 Pro Bono Humanum Honoree by Prix Galien USA 2
(Date:7/30/2014)... Of the many sub-groups of cells jockeying for ... not be those that can proliferate the fastest, researchers ... in an advance online publication of the journal ... the treatment of cancer with precision medicines, the study ... are truly driving the tumor,s growth and metastasis and ...
(Date:7/30/2014)... July 30, 2014 Everyone knows that the ... basically everyone. Whether people are looking for something to buy, ... a dentist, the internet is pretty much always going to ... Dental in Lauderdale Florida is so happy to announce the ... web presence into the modern age. Whether a person wants ...
(Date:7/30/2014)... Dallas, Texas (PRWEB) July 30, 2014 ... provides key market data on the North America Contrast ... of US dollars, and volume (in units) and average ...     CT Injectors ,     Interventional Cardiology/Angio Injectors ... medium (or contrast agent) is a substance used to ...
(Date:7/30/2014)... (WAVES) conference is coming to Fairfield, Iowa,s Maharishi University ... August 3. To watch the main plenary talks, visit ... such a large and diverse group of Vedic scholars ... relevance of ancient Vedic knowledge in today,s world. Topics ... and reflections on the various Vedic texts. , The ...
(Date:7/30/2014)... Naomi Fried, PhD, and Alexis Gilroy, ... of the American Telemedicine Association (ATA). The ... a mission to promote professional, ethical and equitable ... technology. , “Both Naomi Fried and Alexis Gilroy, ... and are well known experts in their respective ...
Breaking Medicine News(10 mins):Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4Health News:Vedic living in a modern world: International conference at Maharishi University 2Health News:Vedic living in a modern world: International conference at Maharishi University 3Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2
... The Justice Department,today announced that it has reached ... is headquartered in Southfield, Mich., under the,Americans with ... Weight,Loss Clinic refused to serve a prospective client ... of today,s agreement, Medical Weight Loss Clinic will,provide ...
... to announce the arrival of newly FDA-approved Evolence®--the latest injectable ... beauty treatments. EVOLENCE® utilizes highly-purified porcine Type I collagen, regarded ... identical similarity to human collagen. , ... ...
... G.,Rendell today issued an executive order regarding the ... after the law,authorizing its operation expired on June ... when PHC4 was allowed to "sunset",by the General ... The Rendell administration is committed to creating ...
... serve a distinct advantage on, the road to recovery, said Carl ... ... July 8 The Mariners Inn shelter and treatment,center in downtown Detroit is ... chief operating officer., "Both Jim and David are outstanding leaders in the ...
... Reductions in Iron Blood Levels Associated with Decreased Cancer Risk ... peripheral arterial disease who participated in a randomized controlled trial ... had a reduced incidence of cancer relative to men in ... studies have suggested that lower levels of iron in the ...
... Act yet to show drop-off in access predicted by ... patients have not lost access to care despite federal ... recent years, a new report finds. , Critics feared ... would make treatment more difficult, but investigators from the ...
Cached Medicine News:Health News:Justice Department Reaches Settlement Agreement With Medical Weight Loss Clinic 2Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 2Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 3Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 2Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 3Health News:Mariners Inn Announces New Executive Leadership 2Health News:Also in the July 8 JNCI 2Health News:Also in the July 8 JNCI 3Health News:Also in the July 8 JNCI 4Health News:Cancer Care Unaffected by Doctor Reimbursement Changes 2
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... The Affinity pacemaker ... today's smallest, truly automatic ... effective combination of advanced ... Affinity DR pacemaker incorporates ...
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... The Guidant INSIGNIA Ultra ... patient-specific, easy-to-use features for ... enhanced patient safety. All ... programmed using the ZOOM ...
Medicine Products: